Cognoa CEO to Participate in the Cowen and Company 40th Annual Healthcare Conference

PALO ALTO, Calif. — February 26, 2020 — Cognoa, the leading digital therapeutics company focused on pediatric behavioral health, announced today that CEO, Brent Vaughan, will participate in a digital therapeutics panel discussion at the Cowen and Company 40th Annual Healthcare Conference with executives from Akili Interactive Labs, Click Therapeutics and Pear Therapeutics. The panel will take place at 1:30…

Autism Learning Partners and Cognoa Announce Partnership to Enable Earlier Access to Care

PASADENA and PALO ALTO, Calif. – February 11, 2020 –  Autism Learning Partners (“ALP”), a national leader in the treatment of autism and other developmental disabilities, and Cognoa, the leading digital therapeutics company focused on pediatric behavioral health, announced today a partnership designed to accelerate the diagnosis of autism to enable interventions earlier, when there is the greatest potential to…

Cognoa Executives to Speak at DTx West 2020

PALO ALTO, Calif. — February 10, 2020 — Cognoa, the leading digital therapeutics company focused on pediatric behavioral health, announced today that three company executives will be on stage at the third annual DTx West 2020, taking place in San Mateo, California, February 18 to 20.   All events take place on the first day of the conference, Tuesday, February 18.…

Cognoa Named to the 2020 Global Digital Health 100 By The Journal of mHealth

International Health Technology Publication Annual List Recognizes Innovation and Leaders in Health Technology Palo Alto, Calif., and London – January 29, 2020 –  Cognoa, the leading digital therapeutics company focused on pediatric behavioral health, has been named to the 2020 Global Digital Health 100 list by The Journal of mHealth. Cognoa’s digital therapeutics will advance the standard of care by…

Cognoa CEO and CMO Presenting at Digital Medicine & Medtech Showcase 2020 and Innovator MD Global Summit in San Francisco

PALO ALTO, Calif.- January 6, 2020—Cognoa, the leading digital therapeutics company focused on pediatric behavioral health, announced today that senior executives will be speaking at two healthcare innovation and investor conferences in San Francisco. ● Brent Vaughan, CEO and co-founder of Cognoa, will provide an update on the company’s milestones and strategy at the Digital Medicine & Medtech Showcase™ 2020,…

Cognoa Wins 2019 Fierce Innovation Life Science Award

Palo Alto, Calif., December 18, 2019 –  Cognoa, a company at the forefront of pediatric behavioral health, has won the Fierce Innovation Life Science Award for Technology Innovation. Cognoa’s digital therapeutics will advance the standard of care by giving every child the opportunity to receive treatments earlier when they can have the greatest impact. Currently, diagnosis and treatment of behavioral…

Cognoa Selected as Finalist in Fierce Innovation Awards – LifeSciences Edition 2019

Cognoa develops AI-powered digital therapeutics and medicines that advance the standard of care in pediatric behavioral health and improve lifelong outcomes for children Palo Alto, Calif., December 5, 2019 –  Cognoa, a company at the forefront of pediatric behavioral health, announced today that it has been selected as a finalist in Questex’s Fierce Innovation Awards – LifeSciences Edition 2019, a…

cognoa-logo

Cognoa Appoints Seasoned Biotech Executive as CFO

James Welch brings two decades experience scaling high-growth companies to Cognoa as company prepares for commercialization PALO ALTO, Calif.– December 2, 2019 –Cognoa, a company at the forefront of pediatric behavioral health, announced today that James (Jim) H. Welch has been appointed Chief Financial Officer. Welch will oversee financial planning, operations and investor relations as the company advances its digital…

cognoa-logo

Cognoa Launches Pivotal Study of the First Digital Diagnostic for Autism.

Palo Alto, Calif., Oct. 24, 2019 (GLOBE NEWSWIRE) — Cognoa, a company at the forefront of pediatric behavioral health, announced today initiation of its Pivotal Study to demonstrate the effectiveness of its diagnostic aid for autism spectrum disorder (ASD). The company anticipates submitting the results of this multi-site, prospective, blinded, active comparator study to the U.S. Food and Drug Administration (FDA)…

cognoa-logo

Cognoa and EVERSANA™ announce partnership to advance the commercialization standard for prescription digital medicines.

PALO ALTO, Calif. and CHICAGO, Sept. 10, 2019 /PRNewswire/ — Cognoa, a company at the forefront of pediatric behavioral health, and EVERSANA™, the leading independent provider of global commercial services to the life science industry, today announced a partnership to advance the industry standard by which digital medicines will be ordered, dispensed, and covered by insurance. By leveraging the existing healthcare infrastructure utilized by pharmaceutical companies…

Location

Social